Clinical Trial

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-08-25; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2023-08-25
Trial Details
NCT Number NCT05519579
Lead Sponsor Northside Hospital, Inc.
Conditions Acute Lymphoblastic Leukemia
Enrollment 20 participants
Start Date 2023-06-30
Primary Completion 2026-11-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-20